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Hypertrophic Cardiomyopathy
Obiter Dictum or More?We greatly appreciate the positive comments offered
by Drs. Jan and Tajik regarding our contemporary
review of diagnostic and management strategies for
hypertrophic cardiomyopathy (HCM) (1). However,
Drs. Jan and Tajik point out that we have ignored
the role of obstructive sleep apnea (OSA) in the
clinical course of patients with HCM. On reﬂection,
we agree that it was perhaps an oversight not to
at least mention OSA, given the increasing data
suggesting that OSA may contribute to drug-
refractory symptoms and left ventricular outﬂow
gradients in this disease (2,3). On the other hand,
we believe that it is probably premature to consider
OSA to be a sudden death risk stratiﬁcation markerin HCM, given the limited observational data that
are currently available. Nevertheless, because the
HCM risk factor algorithm remains incomplete (4,5),
additional relevant variables would represent a
signiﬁcant contribution to disease management.
Given its inﬂuence on clinical outcomes in a variety
of cardiovascular diseases, OSA warrants further
investigation in this regard.*Barry J. Maron, MD
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